John R. Stuelpnagel, D.V.M. has been Chairman of our board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel served as the Chairman of Fabric Genomics from August 2009 through April 2025 when that company was sold to GeneDx and the Chairman of Inscripta from April 2017 to April 2025 when that company was merged with Manus Bio. He has been the Chairman of Manus Bio since April 2025, a member of the board of directors for Encoded Therapeutics since May 2017, and a member of the board of directors for Volta, Inc. since May 2025. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked in various capacities including Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and a member of the board of directors until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles. WE BELIEVE THAT DR. STUELPNAGEL IS QUALIFIED TO SERVE ON OUR BOARD OF DIRECTORS BECAUSE OF HIS EXPERIENCE AS A CO-FOUNDER OF LIFE SCIENCES AND PHARMACEUTICAL COMPANIES, PREVIOUS AND CURRENT EXPERIENCE SERVING AS A DIRECTOR AND EXECUTIVE OFFICER OF OTHER LIFE SCIENCES COMPANIES AND HIS EXTENSIVE EXPERIENCE IN BUSINESS.